proteins, likemonoclonal antibodiesand cell signaling proteins. Unlike most chemically-derived small-molecule drugs, biological products are generally derived from a living organism, such as humans, animals, microorganisms or yeast. Clinically, they are used to treat patients with cancer, kidney diseases...
AREG has been suggested as a good target for treating cancer, inhibition of AREG by siRNA or monoclonal antibodies results in apoptosis of cancer cells or shrinkage of mice xenograft tumors.15,61,83 Our study showed that transfection of SKOV-I6 cells with miR-34c-5p resulted in significant ...
(PDP) initiative was developed for the local manufacturing of 14 biological drugs seven of which are monoclonal antibodies (mAb) [ 7 ] that involve facilities with greater complexity and unique manufacturing processes.The manufacturing process is important for all drugs, but especially for biological ...
To assess the therapeutic potential of monoclonal antibodies targeting T helper (Th) subset differentiation determining cytokines, we studied a murine model of anti-myeloperoxidase glomerulonephritis. The temporal participation of T helper subsets was determined by quantitating gene expression of CD4+ T-...
上海玉博生物科技有限公司 主要致力于“ARE-BLA HEP G2 CELLS Invitrogen-K1633”的生产销售。多年的“ARE-BLA HEP G2 CELLS Invitrogen-K1633”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我公司经营的产品名称深受广大用户信赖。欢迎来电咨询或前来选购
In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are n
and IL-10 levels are positively correlated with disease severity. Current clinical anti-IL-10 secretory agents for the treatment of SLE are mainly anti-IL-10 monoclonal antibodies and other drugs that have proven effective in small-scale trials. In-depth studies on the role of IL-10 and its...
The complex science around mRNA is very different from that of small molecule traditional pharmaceuticals or traditional biologics such as monoclonal antibodies. This month we speak to Christy Eatmon, Global SME, Sterile Drug Products, Pharma Services Group at Thermo Fisher Scientific about how CDMOs ...
Monoclonal antibodies Monoclonal antibodies have gained popularity for the treatment of various hematological malignancies. They potentially allow for more narrowly directed therapy for these diseases by targeting specific antigens expressed on the cell surface of malignant cells. However, normal hematopoetic...
On the other hand, these very same patients could be treated in the future with Imood biologics i.e., neutralising antibodies against Imood that would bring back to physiological levels the concentration of Imood in blood. The development of this translational program of research should go side ...